Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daphne W Bell

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Cancer Research|August 3, 2007
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutationNadia Godin-Heymann, Ianthe Bryant, Miguel N Rivera, et al.
Plos One|January 26, 2022
KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomasMeghan L Rudd, Nancy F Hansen, Xiaolu Zhang, et al.
Cancer|September 24, 2017
The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomasMatthieu Le Gallo, Meghan L Rudd, Mary Ellen Urick, et al.
Cancer Research|October 19, 2006
Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK proteinJingyung Hur, Daphne W Bell, Kathleen L Dean, et al.
Nature Genetics|November 1, 2005
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFRDaphne W Bell, Ira Gore, Ross A Okimoto, et al.
Cell|March 12, 2003
DOCK4, a GTPase activator, is disrupted during tumorigenesisVijay Yajnik, Charles Paulding, Raffaella Sordella, et al.
Gynecologic Oncology|May 26, 2005
Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancerEunice L Kwak, Kenneth H Moberg, Doke C R Wahrer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Nature|December 22, 2007
Isolation of rare circulating tumour cells in cancer patients by microchip technologySunitha Nagrath, Lecia V Sequist, Shyamala Maheswaran, et al.
Blood|February 27, 2008
Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemiasWoo Jae Kim, Ross A Okimoto, Louise E Purton, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Cancer Research|August 3, 2007
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutationNadia Godin-Heymann, Ianthe Bryant, Miguel N Rivera, et al.
Plos One|January 26, 2022
KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomasMeghan L Rudd, Nancy F Hansen, Xiaolu Zhang, et al.
Cancer|September 24, 2017
The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomasMatthieu Le Gallo, Meghan L Rudd, Mary Ellen Urick, et al.
Cancer Research|October 19, 2006
Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK proteinJingyung Hur, Daphne W Bell, Kathleen L Dean, et al.
Nature Genetics|November 1, 2005
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFRDaphne W Bell, Ira Gore, Ross A Okimoto, et al.
Cell|March 12, 2003
DOCK4, a GTPase activator, is disrupted during tumorigenesisVijay Yajnik, Charles Paulding, Raffaella Sordella, et al.
Gynecologic Oncology|May 26, 2005
Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancerEunice L Kwak, Kenneth H Moberg, Doke C R Wahrer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Nature|December 22, 2007
Isolation of rare circulating tumour cells in cancer patients by microchip technologySunitha Nagrath, Lecia V Sequist, Shyamala Maheswaran, et al.
Blood|February 27, 2008
Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemiasWoo Jae Kim, Ross A Okimoto, Louise E Purton, et al.
Pageof 7